Home Cart Sign in  
Chemical Structure| 756890-85-4 Chemical Structure| 756890-85-4

Structure of 756890-85-4

Chemical Structure| 756890-85-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Bibi, Iqra ; Kang, Kyung Jun ; Kim, Jung Young ; Mushtaq, Sajid ; Park, Ji-Ae ;

Abstract: The development of boron neutron capture therapy (BNCT) agents and structurally similar radiolabeled counterparts for diagnostic imaging is an area of significant interest. In this study, we designed structurally same compounds, c(RGD-BPA-K)(PEG2-(4-iodophenylbutyl)) (compound 1) and its radioiodinated counterpart, c(RGD-BPA-K)(PEG2-(4-[125I]iodophenylbutyl)) ([125I]1), for efficient BNCT and SPECT/CT imaging, respectively. An albumin-binding moiety was introduced into the compound to enhance the blood circulation time and tumor accumulation. We evaluated the efficacy of compound 1 and [125I]1 in U87MG tumor-bearing mice using SPECT/CT imaging, biodistribution analysis, and inductively coupled plasma mass spectrometry. Both compound 1 and [125I]1 displayed similar pharmacokinetics, high blood retention, and substantial accumulation in U87MG tumors. This study highlights the potential of compound 1 and [125I]1 for SPECT/CT-guided BNCT. The structural identity between the therapeutic and diagnostic agents in BNCT can enhance its therapeutic efficacy. Further structural modifications to increase boron concentration in tumors, as well as thermal neutron irradiation studies, may be necessary to fully explore the potential of our novel BNCT agent.

Keywords: boron neutron capture therapy ; cyclic arginine-glycine-aspartic acid (cRGD) peptide ; albumin binding moiety

Purchased from AmBeed:

Alternative Products

Product Details of [ 756890-85-4 ]

CAS No. :756890-85-4
Formula : C11H13IO2
M.W : 304.12
SMILES Code : O=C(OC)CCCC1=CC=C(I)C=C1

Safety of [ 756890-85-4 ]

Application In Synthesis of [ 756890-85-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 756890-85-4 ]

[ 756890-85-4 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 67-56-1 ]
  • [ 27913-58-2 ]
  • [ 756890-85-4 ]
  • 2
  • [ 27913-58-2 ]
  • [ 756890-85-4 ]
YieldReaction ConditionsOperation in experiment
With sulfuric acid; In methanol; Step A: Preparation of methyl 4-(4-iodophenyl)-butyrate To a solution of 4-(p-iodophenyl)-butyric acid (45.0 g, 0.155 mol) in methanol (1.3 L), was added sulfuric acid (concentrated, 8.4 mL) dropwise and it was stirred at room temperature under nitrogen for 3 hours. The reaction mixture was concentrated on a rota-vapor, the residue was then partitioned between ethyl acetate (700 mL) and saturated sodium bicarbonate aqueous solution (500 mL). The organic phase was separated, washed with brine (2*200 mL), then dried over Na2SO4 and filtered. Evaporation of solvent gave the titled compound as an oil that was used in step B without further purification.
 

Historical Records